Valuation dashboard for Clene Inc. (CLNN) with P/E N/A, P/B -1.93, EV/EBITDA -3.38 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS).
Analysis Summary
Clene Inc. reported revenue of $200000 in the most recent fiscal year, growing at a 5-year CAGR of -0.6%.
Trailing-twelve-month margins: gross margin -110.2%, operating margin -103.0%, net margin -200.6%.
At the current price of $3.86, CLNN has negative trailing earnings (P/E not meaningful) and an ROE of 148.78%. Market capitalisation stands at $49M.
Balance sheet quality for CLNN: current ratio of 0.8. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -1.93 |
| EV / EBITDA | -3.38 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CLNN | Clene Inc. | $49M | 148.8% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $3.86 |
| Market Cap | $49M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 148.78% |
| Return on Invested Capital | -188.63% |
| Return on Assets | -144.35% |
| Gross Margin | -110.15% |
| Operating Margin | -10304.57% |
| Net Margin | -20059.90% |
Related companies: CNTB · CNTX · COYA · MGNX · ORMP · OVID · PLRX
Explore sector: Healthcare · Biotechnology
More sections of CLNN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks